This issue talks about how Biotech industry slowdown can be avoided. This is a Bio-Entrepreneurship special issue which talks about latest biotech ideas worth executing and also latest information in Industry as well as research and innovation.

CSIR Raman Research Fellowship 2019-2020 notification is out.

This issue covers the story of a  young vibrant personality who raised to success and fame in the healthcare sector, the space which is largely dominated by the male peers. As she ventured into the entrepreneurial road, she not only grabbed the investor's trust but became media's favourite. Attaining the feat of being a billionaire before turning 30 was after all a no minor feat! But the fairytale rise of Elizabeth Holmes’ Theranos soon came to a horrendous fall. Find out the truth behind its speculated fraud, revoking its California lab license and banning the charming young entrepreneur from the business for at least two years in this issue. 

Other articles to interest are “The DeepMind controversy- is patient data at risk”, article on “AI, Robotics and Biotech” , “Ebola sets for a scathing re-entry”, “Turning waste into wealth” and more.
 
Our utmost gratitude to Mr. Vijay G. Pande, Managing Director, Vijyoti and Mr. R.P Mishra, Director, Innovation LifeSciences for sparing their precious time and interacting with Biotecnika magazine.

The deadly wrath of Zika might soon be at rest and more treatments could be pouring in to cure it and more methods at its way to control its spread. It could be achieved now as the most gruelling task of decoding the entire structure of the virus has been achieved by a group of researchers from Purdue University. 

The issue not only covers how the virus structure was unveiled but also the proud moment of an Indian being the part of this extraordinary finding. 
Ms. Devika Sirohi, a PhD scholar at Purdue, was the youngest member of the team who decoded Zika virus structure. Read the exclusive coverage on this young scientist, the findings of the research and what it could hold in the future. 

Other features included in the issue are “Super 13: the world of X-men and superhumans is here”, “GMO special article: Would losing on GMO take a toll on environment, economies too?”, “Why are billionaires investing if BT has no scope?” and more.
 
Special thanks to Mr. Ketan Zota, Director, Zota Healthcare and Mr. Robert Balderas, VP, Market Development, BD Biosciences, USA who took out precious time from their busy schedule to interact with Biotecnika magazine.

There is no denying in the fact that the ‘women-force’ forms the most substantial and effective workforce, and that they have stood at par with the male counterparts at every levels and at every field. In life science sector too, they have not only busted the popular belief that entrepreneurship is a male dominated area but also proved their prowess beyond exceptional. Celebrating the success and opulence of women in the life science industry, we have picked out 10 such names that made it big in the industry and with much aplomb. However with the ever growing life science and biotech sector, the success stories are not limited to these 10 names but reaches far beyond.
 
Other stories to interest are “Storing Brain to computer- the unrealistic way!” which talks about the idea of being immortal by transferring brain to computer, “Monsanto- India spat and whether it would risk GM prevelance in the country”, “What Budget 2016 has to offer to the life science sector” and much more. Also read the conversation of Biotecnika magazine with Mr. Niven N Narain, CEO and Founder, Berg Heathcare.

The unchecked spread of virus created a situation of panic in major parts of the globe to an extent of a "Global health emergency" being declared by the WHO. "Zika", the miniature devil wrecked the lives of many especially infants who were being born with deformity called "microcephaly". While many linked it to Zika, there were also theories of it being spread by an experimental pesticide by Monsanto which was used in Brazil. Amidst the miseries, controversies, speculations and cures, Zika wrath has surely made an headline and we have covered the various aspects of Zika in this issue. 

More in this edition are the controversy around cultivation of GM mustards,  the affect on Indian exporters of mandate by the US government to manufacture APIs locally, a fun read on body parts that we no longer need  to name a few.

A special thanks to Dr. Shivendra Bajaj, Executive Director, ABLE-AG and to Mr. Amit Chopra, MD ThermoFisher India and Mr. Mark Field, CTO, ThermoFisher who interacted with us.

Being a BT professional in India is often speculated as the path towards struggle and why not- it is often surrounded by questions like will it pay me the best, does it offer enough pay hikes, do I have a job security and many more. But this new year might bring a smile to the BT professionals in India as the salary survey conducted by Mercer’s All Industries Total Remuneration says that it might witness the highest pay rise in the year 2016! Amidst the expectations of an increase in the base salaries of overall industries by 10.5%, life science domain would get lucky in terms of hike. The covers story speaks about the same which makes up for a must read. 

Other stories to interest are start-up scheme by Modi and how it could enhance biotech business in the country,  focusing on the talks of the science connoisseurs in the Indian National Congress held at Mysore which focuses on inventing in India, Samsung embracing biotech business and stepping into the lines of Google and much more.

Special thanks to Dr. Ramesh Raliya, Research Scientist, Nano Research facility, Washington University for interacting with Biotecnika magazine. The issue also covers an interaction with Mr. Ankur Parikh, Director, Industrial UV at Alfaa UV. Also read tete-a-tete with Mr. Mark Field, CTO and Mr. Amit Chopra, MD, ThermoFisher India at the inauguration of New Emerging Digital Technology Centre at Bangalore.

A very happy new year from the entire team of Biotecnika to its readers! While another year unfolds with its blank pages to be filled afresh, we hope for another action packed year. When it comes to biotechnology there were many stories that made headlines, but as the year was trending towards end, what caught everyone’s attention was the biggest fraud committed in the sector in 2015. Quoted as the “biotech biggest fraud” and the man involved in it as the “most hated man” in the entire globe, this new year special issue brings to you a story of success, greed and eventually a lesson that could be learnt from- story of Martin Shkreli and his unrealistic drug price hike and other frauds.
 
Many more stories that promises to keep readers engaged are “Captagon- Captivating ordinary to extraordinary!”, “Environmental chaos and biotech solution”, “Top 10 biotech/healthcare firms backed by Google and much  more. Special thanks to Dr. Maryam Sadeghi, Director, Digital Health Hub at Simon Fraser University and CEO & Founder at MetaOptima Technology Inc and Mr. Samartha Jain, CEO & Founder, Positive Biosciences for their precious time.
 
Grab your New Year special issue now!

Promoting women entrepreneurship, green solutions and development of eco-friendly techniques are on their agenda and are determined to make it a reality very soon! We are talking about the two women entrepreneurs Gayathri Thankachi and Aadra Chandra Mouli, who are currently leading the biotech company Aeka Biochemicals based in Kerala. They are focused on serving the society through Aeka while staying green in all ways.

Aeka manufactures biotechnological, biochemical & enzymatic products, chemical products or extracts of biological origin, and can be applied directly or indirectly in the development of products for relevant uses. In this issue read the story of Gayathri Thankachi and Aadra Chandra Mouli, the women entrepreneurs and founders of Aeka Biochem, who lead the first women owned biotech company. Other stories to grab your interest are Reversing aging, How Theranos, a successful biotech company rose and fell, Antibiotics and if they are nearing an end, Top 10 bioindustry trends for 2016 indicating the most importantly upcoming biotrends for the coming year and many more.

Special thanks to Dr. Amol Raut, CEO, GeneSupport; Shiladitya Sengupta and Ms. Dorothy Lou, Lead Business Development, Transcriptic (US) for their valuable contribution in bringing together their opinions on various verticals of bioindustry.

Grab our copy and be a part of the latest from the biotech industry! Subscribe now!

A successful road taken towards entrepeneurship in itself is a story to be inspired from and when the leader in the picture is a 30 year old Indian biotech entrepreneur, it could afford no miss even by a blink. In this issue read the story on Vivek Ramaswamy, an American based CEO who fetched world's largest IPO in biotech from an outcasted drug by GSK. Other stories to grab your interest are Artificial intelligence and if it has the potential to serve as a fairer option to drug discovery, Biosimilars and if India is competent enough in dealing with it, Top 10 pharma firms of 2015 based on their market capital and many more.

Special thanks to Dr. Geeta Shroff, the brain behind human stem cell line and Mr. Sunil Bhambarkar, President, Gattefosse India for their precious contribution in the making of their story, David Green, International biotech communication expert and Dr. Shivendra Bajaj, Executive Director ABLE AG for throwing an insight on GM technology.

It has been two successful years since Biotecnika magazine has taken stage and after traversing for two years, our ardor to serve the biotech industry has just doubled. With this edition, we celebrate the second anniversary of the magazine by highlighting the dedicated support to the industry, initiatives to promote the sector, looking at flaws for the betterment of the sector and much more. With this in mind, Biotecnika once again covers the topic that needs to be looked upon from a common man’s perspective.

As part of the cover feature, we have Dr. VA Shiva Ayyadurai in an exclusive interview with Biotecnika Magazine. The biotech industry was much appalled when the proclamations by Dr.VA Shiva about the rampant corruption inside the gates of CSIR hit the news-stands. He was in and out of CSIR within 5 months of his hiring, as his report claims of underlying bureaucracy inside the organization, questioning the credibility of CSIR. Listen to Dr Shiva himself as he uncovers the complete story in this issue.

Also, the interest levels reach an acme as we have on board Dr. Sergio Canavero, the first person behind the human head transplant initiative. Do not miss an exclusive feature on Prof. Canavero as the professor interacted with Biotecnika magazine, as part of its second anniversary special issue.
 
While October issue is all about celebrating the second anniversary, we included features in the order of 24 issues-24 milestones, Digital India's impact on healthcare, Is polio staging a comeback?' and our ardent support to GM technology.
 
This anniversary, grab our copy and be a part of the latest from the biotech industry! Subscribe now!

While the government is too keen on implementing DNA Profiling Bill in the upcoming Parliamentary sessions, not everybody seem to be convinced with the much controversial bill, and why not? The Bill raises some serious concerns such as how far is the data secured? Would the DNA bank assure no infringement with the privacy of the data? Are strong regulatory bodies set in place to oversee the Bill and much more? The current issue of Biotecnika magazine covers the complete gist of the DNA Profiling Bill 2015- a must have & read!

Apart from this also read topics to interest the human ingenuity such as Super human genes, Cloud Computing, Top 7 Bioprinting breakthroughs of 2015”, tete-a-tete with Mr. Robert Nass, VP, Quality and Regulatory Management, Merck, coverage of inauguration ceremony of Thermo Fisher’s Technology Development Centre and a lot more! Grab your copy now to keep yourself at par with the industry updates.

Controversies hovering food industry are many, but one recent entry has pushed the industry into a precarious situation. The most favourite breakfast snack, Maggi, was banned by the Indian authorities, post which, people are beginning to doubt every packed food on the grocery store shelf. The issue has triggered a fear and also fury among the loyal bunch of consumers. As Nestle was pointed fingers at, there were also questions raised on the authenticity of the food quality analysis as carried out by the India Quality Control Analysts. Trying to analyse whether the brand was truly a killer or did it just mistakenly land into trouble, forms the background for our August issue cover feature titled, “Maggi: Silent killer brand or silently killed?”
 
Moving along, other features to interest you include CRO market, Top 7 CRO companies in emerging markets, Can GMOs offer solace to environmental crisis, and Surging insulin market. Also featured are the interviews with Dr. Amar Desai, Research associate at Case Western Reserve and also one of the research team members behind ‘Tissue regeneration drug’ and Mr. Ambuj Jain, India General Manager at Cambridge Consultants. Do not miss on what they had to say on the Indian bioresearch and pharma industry. Grab your copy now!

Along with the advent in technology that biotechnology has favoured to mankind, in rare cases there have been findings that could not go down well with people. GMOs are one such overly criticized technology which has received more suspicion than praises. In a false propaganda against GM crops, myths tend to weigh more than truth about it- for which media to a great extend could be blamed. With exponentially increasing population that could soon be followed by a shortage of food worldwide, GM technology could actually prove to be a boon, albeit anti GMO NGOs stop opposing. July cover features the same under the title “It’s time to prosecute anti-GMO NGOs- Combating false propaganda against GMO companies”.
 
Other stories to keep the interest up are “How to start a company in biotech”, “Will you get your genome sequenced- a global picture”, ‘Top 10 employers in biotechnology” and much more. Also featured are the talks with industry stalwart- Mr. Sumit Mitra, Global Marketing Manager, MolBio Diagnostics and Mr. G.S Krishnan, Regional President, Novozymes. What are you waiting for; grab your copy today to get new insights into the industry with Biotecnika magazine!

EditorBiotechnology sector is quite infamously famous for often receiv-ing the new comers into the industry quite coldly. Be it in terms of infrastructure, getting required approvals or even fetching investors, a bio-preneur’s tale has many villains to overcome before they could actually celebrate a success story. The June issue is dedicated to all the start ups in the industry who have tried hard to make a mark and to those who are still in the rising. The cover story revolves around the ‘hide and seek’ between biotech start ups and the investors and how compatible do they stand out compared to other sectors. Though biotech sector stays ambitious in terms of reaching a top spot in the charts but do we have enough opportunities for its people? We talk about the profit, but is there patience to wait for the returns? Quite sadly, no. Investors, who are mostly in a jiffy of looking for short term benefits often neglect on the huge profits that biotech could bring. There are a lot of strategies and improvements which if adopted could drastically change the scenario. Although in bits and pieces, we are heading towards that layout which is supportive of bio-preneur taking its step smoothly into the sector. Give a definite read to this biotech entrepreneur and investor relationship existing in India in the ‘BT start up special’ issue.

The Indian biotech sector faced a major turn of events when Daiichi Sankyo, Japanese firm whose hide and seek with Indian drug company Ranbaxy came to an end as it decided to sell off its entire holding of  Sun Pharmaceutical Industries and exit Indian pharma sector after a struggle of eight years. Why it had to offload Ranbaxy and what is in store with the company’s future businesses, find out in Biotecnika magazine’s May 2015 issue. Other stories to keep reader’s interest intact are “India succumbs to H1N1”, “Are we amid biotech bubble”, “Is it time to kill your R&D project?” and much more. Biotecnika bureau had a chance to interact with Ms. Anu Acharya, CEO, Mapmygenome on her entrepreneurial voyage and Dr. Anurag Mathur, Lead author, “Heart-on-chip” on his recent research. Grab your copy to find out what they had to say!

The surge in technology has made our lives easy in every form and its contribution towards improving healthcare is surely commendable. With an increasing trend in healthcare apps, Apple Inc. has taken a step forward and has brought in a concept of ResearchKit which has nested apps for various diseases such as asthma, cardiovascular ailments, Parkinson and much more. It allows its users to conduct tests and take part in studies hence claiming to revolutionize the way data is generated for clinical studies. Will Apple ResearchKit be a big hit? Read Biotecnika April issue to find out more on it. The issue also covers topics to interest such as “Top 10 biotech spenders”, “Budget review 2015”, “Increasing support for GM crops and much more” . Also read interview coverage of Mr. Neeraj Kathuria, Chief Manager, IKP – BIRAC Regional Innovation Centre and Ms. Maggie Massam, Head, Business development, Clinical Practice Research, Data Link, UK at BioAsia 2015. Grab your copy now!

Budget 2015, new government and newer hopes. As a new financial year is all set to begin, the budget is looked upon with expectations from all spectrums. Amidst a plethora of hopes, would the biotech sector, which is on its way of embarking a new zenith, receive equal attention as others? Covering thoughts and expectations from various industry patrons on the same, we have carved out our cover story as “Budget 2015: Would the country’s CFO endorse Biotech sector?” The other stories to interest our readers are the updates and interviews from the likes of Mr.Jupally Krishna Rao, Minister of Industries and Commerce, Telangana, Dr. Mak Jawadekar, former R&D Director, Pfizer, Dr. CSN Murthy, CEO, Aurigene, Founder of start-up, eKincare from BioAsia 2015 held in February, “Top 7 Indian serial entrepreneurs”, a contribution by Novozyme “Re-think tomorrow with fuel from wastes” and much more. Grab the copy now and stay updated with the leading magazine of bioscience sector.

With Modi taking over the helm of the country, a string of hopes came attached with it. And with expectations flowing in for improvement in all the sectors, dearth in biotechnology sector remains the most awaited one to be addressed. Will the change in strategies and policies bring about the desired change in the sector? Will ‘Modi’nomic strategies be able to modify biotech sector? Read along with the February issue of Biotecnika magazine to have a look on the same. Various other latest happening of the bioscience world are covered under the headings “Ebola Outrage, is a cure round the corner?”, “Could artificial womb bring the next big technological revolution?”, a write-up by Novozymes on their Bioagricultural aspect and much more. The issue would have been incomplete without the precious support extended by Mr. Ramesh Swaminthan, CFO, Lupin. So, wait no more and grab your copy to stay updated with the latest industry trends.

With New Year comes new hope and expectations to upbeat the last year achievements and set newer targets for the days ahead. The one sector where the professionals strive for a hopeful future is Indian Biotech Industry. Infamously famous for unsatisfactory growth and peanut salaries, we wish this year brings a bunch of reasons to celebrate. Carving our cover story around the salary structure of a biotech professional this New Year, the issue offers a story on “Salary Special” and covers every element to decide “Who pays you the best in Biotech sector”. To further keep the interest intact, we have penned down articles from various verticals of bioscience domain such as “M&A- hurting or helping the industry”, “Google enters sequencing space”, “Will Modi’s Make in India change the fate of GM crops” and much more. The issue would have been incomplete without the gracious support from Dr. Anand, CEO, Bugworks and Titan Biotech who helped us to have an insight into the biotech industry and rest the curiosity of readers at peace. Grab your copy this New Year to get a fresh insight on biotech sector!

When the world is unassertive of advocating the usage of gene modifying technology, the world’s most populous country has stepped its foot forward in promoting GM food through all forms of media. While most of the developed countries still avert the usage of GMO’s, the step taken by China is quite commendable. This issue we have weaved our cover story around the same talking about “GM crops-Promotion vs. Relegation”. To interest our readers further, the issue also features “Eating Chicken or Antibiotics”, “GM labeling- is it our right to know?”, “Google further leaps into bioresearch” and much more. We would like to mention special thanks to Dr. Surinder Kher, CEO, Ecron Acunova and Mr. Jhenkar Dixit, CEO, GridOctane for their time and support. The issue also features Proteomics Lab inauguration by Thermo Fisher Scientific in the BT capital of India. Don’t let the best from bioscience sector go amiss. Grab your copy now!

With newer government came newer policies and hence newer hopes. One among those is the recent 'Make in India' initiative by Modi government. Emphasizing on attracting investors and hence improving job opportunity, it raises hope on dealing the lacuna that biotech sector faces, particularly the dearth in investments. The current issue of Biotecnika magazine analyses if Make in India would prove to be a stylish attempt to attract investments to BT sector? The other features to interest readers are 'Imminent second green revolution', 'CO2 to plastics- GE microbes answering global pollution', 'Delaying aging- an answer to delaying diseases?' and many more. Also see the feature covering Titan Biotech and Siro Clinfarm. With  much more to acquaint yourself with, wait no more and grab your copy now!

Biotecnika Magazine celebrates its first anniversary! In this festive season, as we celebrate our successful one year, catering to thousands of readers from bio community, we hope to improve upon the best further as well! We express our gratitude to our readers and mentors for all their appreciation and support. The cover feature of October issue details on how IT majors have been backing biotech industry and proving to be a ray of hope for biotech sector. With Google, SAP, Infosys and more IT giants extending their funding and support to biotechnology, the future of the industry definitely stands at a better place. An opportunity to interact with Novozyme Regional President, GS Krishnan; Dr. Jagadish Mittur from KBITS and New Horizon Group of Institutions and include excerpts from respective interviews, has been a valuable addition. To further interest the readers, the issue offers articles titled; “The battle to be BT capital,” “Recalling the exemption in service tax” and “Is the road to cancer heading nowhere?” Much more awaits! Grab your Anniversary Special Copy and Stay Updated!

When the wrath of deadly Ebola is showing its heinous side by causing a global pandemic and silently taking a toll on population across West African countries, finding a full stop to this problem is what scientists all across the globe are striving for. Biotechnology which has been the answer to many such unforeseen hurdles in the past is being looked upon with high expectations and why not! It has the potential to sway away many major problems. Biotecnika's September issue talks about the same and chalks out, 'If biotech biggies would churn out a remedy soon?' Other topics to interest our readers are 'The battle with HIV--when will we win?', Ban on GMO trials...where is the road taking us?' and much more..The issue also interacted with biotech big names such as Biocon Academy, Stempeutics and Sigma Aldrich to know the industry better. Wait no more and grab your copy of Biotecnika magazine now!

While transitions are utmost necessity of life, is biotech sector witnessing transition at a same pace? Are the expectations from bio-community near fulfillment? Though the roadmap to a perfect biotech culture is far away, the budget allocation for biotech does keep our hopes intact. Featuring the same, the cover story of this issue details on how the budget allocation has been received by the bio community and analyzes ‘Did Modi’s budget quench the thirst of BT sector?’ Other topics to interest our readers are ‘The bionic brain-boon to paralyses’, ‘Genetic identity- to be kept under wraps or unconcealed?’, ‘Bio fortified food’ and so on. That’s not all as the readers get to know industry giants Mr.V.S Reddy, MD, British Biologicals, Ms.Shobha V., Coonexios Life Sciences and Mrs. Mirella Marlow, Programme  Director, NICE, UK.  Wait no more and grab your copy of Biotecnika magazine now!

Academia, believed to be the backbone of a successful career, holds to be a pertinent fit for a bloom in biotech sector. A recipe of perfect mix between the subjective and practical knowledge, biotechnology demands nothing short of a \'perfectly\' equipped manpower for it\'s labs. But are Indian universities on the right track to make such impeccable biotech professionals? July issue covers the complete analysis of \'Is Biotech Academia Going the Right Way? to know what are the pluses and minuses of these universities. Other topics to interest our readers are the very controversial subjects such as \'Contemplating 3 Parent baby Procedure\', \'Futuristic Biotechnology-Fear or Favor?\' etc. It also brings the industry close by interviewing the ingenious personalities from Waters, Thermo Fisher Scientific, GVK and Manipal University. So what are you waiting for? Hop on to grab your copy of Biotecnika magazine to get a complete insight into the biotech world...

Media hypes that can make even the most insignificant junk of a story to a national issue has all the powers to help people form their opinions. Biotechnology being the most controversial yet a significant subjects on the timeline, needs media to be a cupid connecting the masses with science. But is the media obligating towards all the positive aspects? The June issue of Biotecnika magazine covers the different moods of media towards biotechnology under the title \'Is biotech industry facing media bias..? Who do we believe!?\' Retaining the soaring temperature of interests, the issue has \'Patents on seeds and GMOs..Resist or recognize their way into agriculture?\', \'Pfizer & AstraZeneca ..Duo dancing a mega deal\' and \'Indian Intellectual policies..time to turn the corners?\' and much more..Also the interview of Dr. Shekhar Mande, Director, NCCS gives an insight into the bridge that connects industry to academia. Grab a copy of magazine right away to rejuvenate your biotech interests.

To pump up the election fever that India is inundated with, Biotecnika Magazine with this issue adds the biotechnological aspect to the much awaited and anticipated elections. With the parties contesting to win the seats, will it do any good to the blooming biotech and pharma field? Would the manifestos promising the growth, stand out this time? Analysing this and much more, the cover story has all the elements to indulge in for. What\'s more? The magazine offers the readers a look onto the war between Patenters and Infringers that has made a headline recently, the major move of Ranbaxy being bought by Sun Pharma, How Biotech can manage and salvage the waste and much more.. To retain the interests, interview of the Nobel Laureate Dr. Thomas Sudhoff,  Mitra Biotech\'s President and CEO and that of Biozeen\'s Executive Director does the needful... Grab your copy of the magazine to avail the best of biotech industry...

The intensifying eye of FDA on the Indian units of many pharmaceutical and biotech companies has raised many eyebrows on the issue striving to figure out who is correct and who is not. The current issue talks about the same,analyzing and viewing the point of views of both the parties. Apart from the intriguing cover, the issue also includes the wonders of biotechnology such as \'Bio printing\' which assures to be the biopromise of the future. To make the interest of the readers it coves various other aspects of biotech world such as \'Criticism vs Biotech progress\', \' Bioregulators..are you listeing?\' etc. To add the flavor to the coming elections, the views and ideas of political biggies on biotechnology has been potrayed in \'with election on edge..what politicians pledge\'? This and much more awaits you in the April issue of Biotecnika magazine.Wait no more and subscribe to Biotecnika Magazine now...

When the world goes wary with Information technology, biotechnology is all set to steal the show and doing the rounds as perceived by experts. This issue brings in an insight into the persisting scenario in and around IT and BT. Whether BT can match IT is the heated question right now and whether it can do all the wonders that IT did to India is the most awaited answer. Intriguing the reader throughout, this issue offers you the most debatable and high on the spot issues such as \'Patent wars\' and whether \'Recycling is healing or hurting the environment\'. To interest our readers from core research, \'Nanotechnology..A walk into the future and the \'Changing dynamics of Biosupplier industry does the needful. The drawbacks of the current biotechnology scenario in India is crafted out neatly in \'Where we fell short...In our quest to follow the best\'. Keeping yourself updated about the news and the happenings of the bio-world, March issue has every flavor to offer.

This issue highlights fiction with a flight of Bio-fantasy and Cover Story of Emerging Asia-all slated to make a history in biotech world.

BioTecNika  Cover - December 2018 Edition

December 2018

BioTecNika  - December 2018

June 2016

BioTecNika  - June 2016

May 2016

BioTecNika  - May 2016

April 2016

BioTecNika  - April 2016

March 2016

BioTecNika  - March 2016

BioTecNika  Cover - February 2016 Edition

February 2016

BioTecNika  - February 2016

January 2016

BioTecNika  - January 2016

BioTecNika  Cover - December 2015 Edition

December 2015

BioTecNika  - December 2015

BioTecNika  Cover - November 2015 Edition

November 2015

BioTecNika  - November 2015

October 2015

BioTecNika  - October 2015

BioTecNika  Cover - September 2015 Edition

September 2015

BioTecNika  - September 2015

August 2015

BioTecNika  - August 2015

July 2015

BioTecNika  - July 2015

June 2015

BioTecNika  - June 2015

May 2015

BioTecNika  - May 2015

April 2015

BioTecNika  - April 2015

The essential guide to all the news in biotechnology industry & Academia run by India's Most popular Biotechnology Portal www.biotecnika.org. BioTecNika has access to world’s most influential Biotech entrepreneurs, Businesses and institutions. The magazine showcases all this via exclusive features that are insightful, informative and presented with style. 

Distinguished by its indepth analysis and latest information, BioTecNika has been an indispensable part of life of Biotechies for over 8+ years. Our well-heeled readership shape opinions and trends in India and across the region. This affluent and influential group is almost impossible to reach - except through the pages of BioTecNika

1. Du godtar at bruken av Magzter.com, applikasjonen og dens tjenester er på egen risiko. Verken Magzter.com eller dets samarbeidspartnere eller ansatte eller tredjeparts innholdsleverandører garanterer at tjenesten vil være fullstendig uavbrutt eller feilfri eller vanntett mot ondsinnede aktiviteter. De garanterer heller ikke at du vil få de nøyaktige resultatene som forventet eller lovet av nettstedet eller produktet.

11. TJENESTEN OG ALLE PUBLIKASJONER LEVERES PÅ EN «SOM DEN ER»- OG «SOM TILGJENGELIG»-BASIS. MAGZTER, DETS TILKNYTTEDE SELSKAPER, LEVERANDØRER, LISENSGIVERE OG AGENTER FRASKRIVER SEG UTTRYKKELIG ALLE GARANTIER AV ENHVER SLAG, ENTEN UTTRYKKELIGE ELLER IMPLISITTE, INKLUDERT MEN IKKE BEGRENSET TIL DE IMPLISITTE SELGERGARANTIENE, EGNETHET FOR SPESIFIKKE FORMÅL OG IKKE-KRENKELSE. UTEN Å BEGRENSE DET OVENNEVNTE GARANTERER VERKEN MAGZTER ELLER DETS TILKNYTTEDE SELSKAPER, LEVERANDØRER, LISENSGIVERE ELLER AGENTER AT (I) TJENESTEN VIL INNFRI DINE KRAV, (II) TJENESTEN VIL VÆRE UFORSTYRRET, RETTIDIG, SIKKER ELLER FEILFRI (III) INFORMASJONEN SOM KAN FÅS FRA BRUKEN AV TJENESTEN ELLER SOM KAN VÆRE I PUBLIKASJONENE VIL VÆRE NØYAKTIG ELLER PÅLITELIG, ELLER (IV) KVALITETEN PÅ EVENTUELLE PUBLIKASJONER ELLER TJENESTEN VIL INNFRI DINE FORVENTNINGER. DU ER ALENE ANSVARLIG FOR Å SKAFFE OG VEDLIKEHOLDE EN PÅLITELIG INTERNETTILKOBLING OG ENHETEN DIN. MAGZTER ER IKKE ANSVARLIG FOR DIN MANGLENDE EVNE TIL Å LASTE NED INNHOLD. ALT MATERIALE SOM LASTES NED ELLER PÅ ANNEN MÅTE FÅS VIA BRUK AV TJENESTEN, GJØRES PÅ DITT EGET ANSVAR OG DIN EGEN RISIKO, OG DU STÅR ALENE ANSVARLIG FOR EVENTUELLE SKADER PÅ DITT DATASYSTEM ELLER DIN MOBILE ENHET ELLER TAP AV DATA SOM OPPSTÅR FRA NEDLASTING AV SLIKT MATERIALE. INGEN RÅD ELLER INFORMASJON, VERKEN MUNTLIG ELLER SKRIFTLIG, FÅTT AV DEG FRA MAGZTER ELLER VIA ELLER FRA TJENESTEN SKAL UTGJØRE NOEN FORM FOR GARANTI.

2. Du skal vedlikeholde og umiddelbart oppdatere denne informasjonen for å holde den sann, nøyaktig, oppdatert og fullstendig. Du er ansvarlig for å opprettholde konfidensialiteten til kontoen din og passordet ditt, for å begrense tilgangen til datamaskinen din, og du godtar ansvaret for all aktivitet som skjer på kontoen din, inkludert valg og bruk av alt innhold og tjenester.

3. Under ingen omstendigheter vil Magzter.com eller noen person eller enhet eller tredjepart som er involvert i opprettelsen, produksjonen og distribusjonen av innholdet på nettstedet og applikasjonen være ansvarlig i kontrakt eller juridisk for eventuelle skader, inkludert og ikke begrenset til, direkte, indirekte, vilkårlige, spesielle og følgevirkninger som påføres deg mens du bruker Magzter.com. Ved å registrere deg på nettsiden eller laste ned applikasjonen godtar du at bestemmelsene nevnt i denne delen skal gjelde for all bruk av og innhold på nettsiden og applikasjonen.

3. Uten skriftlig eller autorisert tillatelse fra Magzter på forhånd, må du ikke modifisere, kopiere, distribuere eller selge noe innhold hentet fra Magzter, for alt publisert her tilhører Magzter eller dets lisensgivere. Siden slik uautorisert bruk også kan bryte gjeldende lovverk, inkludert lover om opphavsrett og varemerker, forbyr Magzter dette på det sterkeste og vil avslutte tilgangen din og slette kontoen din hvis slik ulovlig aktivitet blir bevist eller oppdaget. Du blir også holdt ansvarlig for skader forårsaket av disse uautoriserte aktivitetene. Med unntak av det som er tillatt av utgivelsens lovlige eier, erkjenner du at du ikke får noen eierskapsrettigheter ved å laste ned utgivelser som du får tilgang til via tjenesten. Med unntak av det som er eksplisitt påkrevd i henhold til lov om opphavsrett eller tillatt av funksjonene i tjenesten, kan du ikke modifisere, reversere, publisere, overføre, vise, delta i overføringen eller salget av, lage avledede verk av, eller på noen måte kommersielt utnytte eller levere innholdet i appen, utgivelsene eller deler av dem til en tredjepart uten uttrykkelig tillatelse fra Magzter og eieren av slikt innhold. Vi gir deg ingen lisenser, uttrykt eller implisitt, for de immaterielle eiendelene til Magzter eller Magzters lisensgivere.

5. Du erkjenner spesifikt at Magzter.com ikke er ansvarlig for noen form for ærekrenkende eller støtende eller ulovlig oppførsel fra andre brukere eller tredjeparter eller deres innhold, og at risikoen for skade fra det ovennevnte ligger helt hos deg.

8. Magzter forbeholder seg alle rettigheter til å overvåke innholdet som publiseres og legges inn av deg for å avgjøre om du er i samsvar med disse vilkårene og betingelsene og andre driftsregler fastsatt av Magzter. Magzter har rett til å ta beslutninger om innholdet og slette dem etter eget forgodtbefinnende.

9. Magzter er distributør og IKKE utgiver av publikasjonene, og Magzter har derfor ingen redaksjonell kontroll over innholdet, inkludert meninger, råd, uttalelser, tjenester, tilbud osv., som er representert i magasinene. Magzter vil ikke ta ansvar for nøyaktigheten eller påliteligheten for informasjon eller fakta gitt deri eller som er gjort tilgjengelig gjennom tjenesten, av andre enn autoriserte Magzter-ansatte som handler i henhold til deres offisielle embete. Følgelig har vi ingen redaksjonell kontroll over publikasjonene. Eventuelle meninger, råd, uttalelser, tjenester, tilbud eller annen informasjon eller innhold uttrykt eller gjort tilgjengelig av tredjeparter, inkludert de som er gjort i publikasjoner som tilbys av tjenesten, tilhører sine respektive forfattere eller utgivere og ikke Magzter. Magzter vil ikke være ansvarlig for tap eller skade forårsaket av at du stoler på informasjon innhentet gjennom tjenesten eller fra publikasjonene. Tjenesten kan inneholde koblinger til andre internettsider og tredjepartsressurser, og Magzter påtar seg ikke noe ansvar for kommunikasjon eller materiale som er tilgjengelig på slike nettsteder via koblinger. Disse koblingene er kun for din bekvemmelighet. Du er alene ansvarlig for å forstå eventuelle vilkår og betingelser som kan gjelde når du besøker eller legger inn en bestilling gjennom en tredjepartsside.

Detaljer om det støtende innholdet, inkludert koblingen dens på plattformen vår

Last ned favorittitlene dine og les dem offline, når og hvor som helst

Gi dine kjære et Magzter-gavekort umiddelbart og gi dem friheten til å lese favorittmagasinene og -avisene sine fra tusenvis av bestselgende titler.

Gi dine kjære et Magzter-gavekort umiddelbart og gi dem friheten til å lese favorittmagasinene sine fra tusenvis av bestselgende titler.

Gi dine kjære et Magzter-gavekort umiddelbart og gi dem friheten til å lese favorittmagasinene sine blant {{magCount}} bestselgende internasjonale titler.

Girish Ramdas er medgründer og administrerende direktør for Magzter, en New York-basert oppstartsbedrift som har laget oppstyr i den globale digitale publiseringsvirksomheten. Magzter har nådd 80 millioner brukere siden oppstarten i 2011 fra mer enn 150+ land med tusenvis av magasiner, aviser og bøker fra mer enn 4500 utgivere over hele verden. Han har mer enn 25 års erfaring innen publisering på tvers av plattformer, inkludert trykk-, mobil- og webutvikling. I løpet av denne perioden har han vært med å grunnlegge og drive tre vellykkede oppstartsbedrifter. Han har gjort det mulig for magasinbedrifter å bli digitale og hjelper dem med å tjene penger på innholdet i den digitale verden. Girish' omfattende bransjeerfaring innen nett-, mobil- og publiseringsøkosystemer har gjort ham til en ekspert på anskaffelse, markedsføring og inntektsgenerering av digitalt innhold på tvers av globale plattformer.

I tilfelle du kommer over støtende innhold på plattformen vår, har vi innført retningslinjer for klagehåndtering for å behandle henvendelsene dine.

Magzter Inc. («bedrift», «vi», «oss» eller «vår/våre») vet at du bryr deg om hvordan personopplysningene dine brukes og deles. Les følgende personvernregler («retningslinjer») for å lære mer om personvernpraksisen vår. Ved å besøke noen av nettstedene som drives av selskapet, og eventuelle underdomener derav, eller ved å bruke noen av våre mobilapper og andre metoder for innholdsdistribusjon (samlet omtalt som «tjeneste»), erkjenner du at du godtar praksisen og retningslinjene skissert i disse retningslinjene, og du samtykker herved til at vi samler inn, bruker og deler informasjonen din på følgende måter.

Magzter Inc. er verdens største og raskest voksende selvbetjente digitale aviskiosk på tvers av plattformer med over 80 millioner brukere siden oppstarten i 2011 og med tusenvis av magasiner og aviser på tvers av 40+ kategorier og 60+ språk. Med hovedkontor i New York, har Magzter lokal tilstedeværelse i Amsterdam, London, Mexico by, Chennai, Mumbai, New Delhi, Bengaluru og Singapore, og vi vil snart utvide til andre land. Magzter ble grunnlagt av de globale entreprenørene Girish Ramdas og Vijay Radhakrishnan i juni 2011, og gjør det mulig for magasin- og avisutgivere over hele verden å lage og levere digitale utgaver av titlene deres for globale forbrukere.

Magzter er forpliktet til å tilby en trygg og sikker plattform til våre brukere. Vær oppmerksom på at Magzter bare er en plattform der utgivere kan distribuere innholdet sitt. Vi kontrollerer eller støtter ikke innholdet som publiseres på plattformen vår. Vi kan ikke holdes ansvarlige for handlingene til våre utgivere eller deres innhold.

Magzter er ikke ansvarlig for å kompensere noen part som har lidd skade eller pådratt seg kostnader på grunn av innhold, eller deler av innholdet, som krenker deres rettigheter. Magzter er ikke ansvarlig for noen rettslige skritt i sivilrett for brudd på rettigheter forårsaket av innhold, eller deler av innholdet, som krenker rettighetene til en tredjepart.

Magzter tilbyr verdens største {{allyoucanread}} abonnementstjeneste kalt {{gold}}, som gir digitale lesere ubegrenset tilgang til 9000+ magasiner og aviser for en månedlig abonnementspris. Magzter har også det største antallet historier i verden med sin revolusjonerende ezRead 2.0-funksjon for appene sine, som lar smarttelefon- og mobilbrukere med små skjermer nyte magasininnhold slik det var ment å bli lest, med artikkeltekst som er lett å lese og med fantastiske videoer og bilder i høy oppløsning.

Magzter tilbyr verdens største «alt du kan lese»-abonnementstjeneste kalt Magzter GOLD som gir digitale lesere ubegrenset tilgang til 9000+ magasiner og aviser for en månedlig abonnementspris. Magzter har også verdens største antall historier revolusjonerende ezRead 2.0-funksjon for appene sine, som gjør det mulig for smarttelefonbrukere og mobilbrukere med små skjermer å nyte magasininnhold, med artikkeltekst som er lett å lese og ledsages av fantastiske videoer og bilder i høy oppløsning.

Navn

Merk: Dette vil bare dele omslaget og utgivelsesinformasjonen, men ikke innholdet.

Fyll ut dette skjemaet hvis du trenger hjelp til å publisere innholdet ditt på Magzter

Før Magzter var han president for Dot Com Infoway (DCI) og Galatta Media. Hans oppgaver inkluderte strategisk markedsføring, partnerskapsutvikling og inntektsgenerering av innhold globalt. DCI vokste fra et lite team på 3 i 2000 til 300 innen 2011 og drev med utvikling av web, programvare og apper for kunder over hele verden.

Siden vi lanserte har Magzter vært forpliktet til å samarbeide med globale organisasjoner for å tilby best mulig aviskiosk-teknologi og -service til kundene våre. Enten du ønsker å tilby magasinabonnement til kundedatabasen din eller bare ønsker å finne ut mer, er Magzter forpliktet til å hjelpe bedriften din å vokse. For å finne ut mer fyll ut spørreskjemaet nedenfor:

DMCA tillater oss å gjenopprette det fjernede innholdet hvis parten som sender inn det opprinnelige DMCA-varselet ikke går til rettssak mot deg innen ti virkedager etter å ha mottatt kopien av innsigelsen din.

Disse retningslinjene dekker selskapets behandling av personopplysninger («personopplysninger») og annen informasjon om deg og din datamaskin eller enhet som selskapet samler inn når du får tilgang til tjenesten. Vi kan samle inn personopplysninger fra deg, som forklart mer detaljert nedenfor, og vi bruker disse personopplysningene internt i forbindelse med tjenestene våre, inkludert for å tilpasse, tilby og forbedre våre produkter, tjenester, innhold og annonser, og for å tillate deg å sette opp en brukerkonto og profil, for å kontakte deg, for å oppfylle dine forespørsler om visse produkter og tjenester, og for å analysere hvordan du bruker tjenestene. I visse tilfeller kan vi også dele noen personopplysninger med tredjeparter, men bare som beskrevet i punkt 4.

Denne tittelen er inkludert i Magzter GOLD-abonnementet ditt

For å analysere kvaliteten på innholdet og gi passende tilbakemeldinger til utgivere

Vi har utpekt en klageansvarlig for å behandle eventuelle klager knyttet til støtende innhold.

Vi ber om at enhver klage relatert til støtende innhold sendes til klageansvarlig via e-post til den ovennevnte e-postadressen. Vi ber også om at du oppgir følgende detaljer når du sender inn en klage:

og appen som gir deg muligheten til å bestille, abonnere og motta levering av ulike magasiner, bøker, nyheter og magasin- og publikasjonsrelatert innhold (samlet kjent som «publikasjoner») og få disse digitale versjonene av publikasjonene levert til deg

c. Vi samler også inn informasjon knyttet til din bruk av applikasjonen for å gi personlige anbefalinger. Hvis du oppgir din brukertilgangen for tredjepartskontoer til oss, forstår du at noe innhold og/eller informasjon i disse kontoene («tredjeparts-kontoinformasjon») kan overføres til kontoen din hos oss hvis du godkjenner slike overføringer, og at tredjeparts-kontoinformasjon som sendes til tjenesten, dekkes av disse retningslinjene.

f. Med personopplysningene vi samler inn kan vi svare på dine forespørsler, forbedre produktene og tjenestene våre, tilpasse annonsene og innholdet du ser, og kommunisere med deg om nye produkter.

er verdens største og raskest voksende, selvbetjente digitale aviskiosk på tvers av plattformer med over 87 millioner brukere siden oppstarten i 2011 og tusenvis av magasiner og aviser på tvers av 40+ kategorier og 60+ språk. Med hovedkontor i New York, har Magzter sin lokale tilstedeværelse i Amsterdam, London, Mexico City, Chennai, Mumbai, New Delhi, Bengaluru, Singapore, og vil snart utvide til andre land. Magzter ble grunnlagt av de globale gründerne Girish Ramdas og Vijay Radhakrishnan i juni 2011, og gjør det mulig for magasin- og avisutgivere over hele verden å lage og levere digitale utgaver av titlene deres til globale forbrukere.

n. Vi vil også bruke bruksinformasjon for å sikre at brukerne overholder våre bruksvilkår. For eksempel vil en brukers bruksinformasjon hjelpe oss med å bekrefte at en bruker bare laster ned magasiner eller annet innhold det tillatte antallet ganger eller til det tillatte antallet enheter.

som gir digitale lesere ubegrenset tilgang til 9000+ magasiner og aviser for en månedlig abonnementspris. Magzter har også det største antallet historier i verden med sin revolusjonerende ezRead 2.0-funksjon for appene sine, som lar smarttelefon- og mobilbrukere med små skjermer nyte magasininnhold slik det var ment å bli lest, med artikkeltekst som er lett å lese og med fantastiske videoer og bilder i høy oppløsning.

{{magzter}} er verdens største og raskest voksende, selvbetjente digitale aviskiosk på tvers av plattformer med over 87 millioner brukere siden oppstarten i 2011 og tusenvis av magasiner og aviser på tvers av 40+ kategorier og 60+ språk. Med hovedkontor i New York, har Magzter sin lokale tilstedeværelse i Amsterdam, London, Mexico City, Chennai, Mumbai, New Delhi, Bengaluru, Singapore, og vil snart utvide til andre land. Magzter ble grunnlagt av de globale entreprenørene Girish Ramdas og Vijay Radhakrishnan i juni 2011, og gjør det mulig for magasin- og avisutgivere over hele verden å lage og levere digitale utgaver av titlene deres til globale forbrukere.

BioTecNika - November 2013

BioTecNika - November 2013

I denne utgaven

BioTecNika Magazine Description: